TY - JOUR
T1 - STAP-2 Is a Novel Positive Regulator of TCR-Proximal Signals
AU - Saitoh, Kodai
AU - Kashiwakura, Jun Ichi
AU - Kagohashi, Kota
AU - Sasaki, Yuto
AU - Kawahara, Shoya
AU - Sekine, Yuichi
AU - Kitai, Yuichi
AU - Muromoto, Ryuta
AU - Ichii, Michiko
AU - Nakatsukasa, Hiroko
AU - Yoshimura, Akihiko
AU - Oritani, Kenji
AU - Matsuda, Tadashi
N1 - Publisher Copyright:
© 2022 by TheAmericanAssociation of Immunologists, Inc.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - TCR ligation with an Ag presented on MHC molecules promotes T cell activation, leading to the selection, differentiation, and proliferation of T cells and cytokine production. These immunological events are optimally arranged to provide appropriate responses against a variety of pathogens. We here propose signal-transducing adaptor protein-2 (STAP-2) as a new positive regulator of TCR signaling. STAP-2-deficient T cells showed reduced, whereas STAP-2-overexpressing T cells showed enhanced, TCR-mediated signaling and downstream IL-2 production. For the mechanisms, STAP-2 associated with TCR-proximal CD3f immunoreceptor tyrosine activation motifs and phosphorylated LCK, resulting in enhancement of their binding after TCR stimulation. In parallel, STAP-2 expression is required for full activation of downstream TCR signaling. Importantly, STAP-2-deficient mice exhibited slight phenotypes of CD4+ T-cell-mediated inflammatory diseases, such as experimental autoimmune encephalomyelitis, whereas STAP-2-overexpressing transgenic mice showed severe phenotypes of these diseases. Together, STAP-2 is an adaptor protein to enhance TCR signaling; therefore, manipulating STAP-2 will have an ability to improve the treatment of patients with autoimmune diseases as well as the chimeric Ag receptor T cell therapy.
AB - TCR ligation with an Ag presented on MHC molecules promotes T cell activation, leading to the selection, differentiation, and proliferation of T cells and cytokine production. These immunological events are optimally arranged to provide appropriate responses against a variety of pathogens. We here propose signal-transducing adaptor protein-2 (STAP-2) as a new positive regulator of TCR signaling. STAP-2-deficient T cells showed reduced, whereas STAP-2-overexpressing T cells showed enhanced, TCR-mediated signaling and downstream IL-2 production. For the mechanisms, STAP-2 associated with TCR-proximal CD3f immunoreceptor tyrosine activation motifs and phosphorylated LCK, resulting in enhancement of their binding after TCR stimulation. In parallel, STAP-2 expression is required for full activation of downstream TCR signaling. Importantly, STAP-2-deficient mice exhibited slight phenotypes of CD4+ T-cell-mediated inflammatory diseases, such as experimental autoimmune encephalomyelitis, whereas STAP-2-overexpressing transgenic mice showed severe phenotypes of these diseases. Together, STAP-2 is an adaptor protein to enhance TCR signaling; therefore, manipulating STAP-2 will have an ability to improve the treatment of patients with autoimmune diseases as well as the chimeric Ag receptor T cell therapy.
UR - https://www.scopus.com/pages/publications/85133215076
U2 - 10.4049/jimmunol.2101014
DO - 10.4049/jimmunol.2101014
M3 - Article
C2 - 35725273
AN - SCOPUS:85133215076
SN - 0022-1767
VL - 209
SP - 57
EP - 68
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -